Detection of erythropoiesis stimulating agent Luspatercept after administration to healthy volunteers for antidoping purposes
Sign Up to like & getrecommendations! Published in 2022 at "Drug Testing and Analysis"
DOI: 10.1002/dta.3341
Abstract: Abstract Luspatercept (Reblozyl®) is a newly approved anti‐anemic drug prohibited by the World Anti‐Doping Agency. It promotes erythropoiesis by limiting apoptosis of immature erythroblasts and the risk of misuse by athletes for doping is high.… read more here.
Keywords: volunteers antidoping; administration; healthy volunteers; erythropoiesis stimulating ... See more keywords